Introduction

Cardiovascular comorbidity is a major burden in patients with chronic inflammatory rheumatic diseases and a significant determinant of their outcome. In addition to optimal management of the underlying inflammatory condition according to current guidelines, individual cardiovascular risk factors, particularly dyslipidaemia, hypertension, and impaired glucose tolerance should be assessed regularly and guide risk stratification and requirement for treatment.

Areas discussed

We critically reviewed manuscripts and guidelines on the pharmacological management of dyslipidaemia, hypertension, and diabetes in patients with chronic inflammatory rheumatic diseases (PubMed, MEDLINE, EMBASE, Scopus, Web of Science and Google Scholar, up to 1 March 2020). Lifestyle changes are of paramount importance for the management of these risk factors. In the current narrative review, we discuss pharmacological therapies available and emerging therapies aiming to help patients achieve recommended targets, depending on their individual risk.

Expert opinion

CVD risk is increased in people with chronic inflammatory rheumatic diseases. Cardiovascular risk factor management is an essential part of their care. Although relevant guidance exists, there are still major gaps in knowledge and risk factor management implementation in these patient groups. Some practical guidance based on our interpretation of existing data and experience in the field is provided in this review.

中文翻译：

---

慢性炎症性风湿病心血管风险的药理学管理。

介绍

心血管合并症是慢性炎症性风湿病患者的主要负担，也是其预后的重要决定因素。除了根据当前指南对潜在炎症状况进行最佳管理外，还应定期评估个体心血管危险因素，特别是血脂异常、高血压和糖耐量异常，并指导风险分层和治疗要求。

讨论的领域

我们严格审查了慢性炎症性风湿病患者血脂异常、高血压和糖尿病药物管理的手稿和指南（PubMed、MEDLINE、EMBASE、Scopus、Web of Science 和 Google Scholar，截至 2020 年 3 月 1 日）。生活方式的改变对于这些风险因素的管理至关重要。在当前的叙述性评论中，我们讨论了可用的药物疗法和新兴疗​​法，旨在帮助患者实现推荐的目标，具体取决于他们的个人风险。

专家意见

慢性炎症性风湿病患者的心血管疾病风险增加。心血管危险因素管理是他们护理的重要组成部分。尽管存在相关指南，但这些患者群体在知识和风险因素管理实施方面仍存在重大差距。本综述提供了一些基于我们对该领域现有数据和经验的解释的实用指南。